El texto completo de este artículo está disponible en PDF.
Human neutralizing antibodies can block COVID-19 infection.
Most monoclonal antibodies inhibit binding S protein to ACE2 receptor.
Researchers are trying to develop treatments based on antibodies to block and/or neutralize SARS-CoV-2.
The genetic and structural similarity of the virus to SARS-CoV helps for designing new methods for treatment of COVID-19.
Coronavirus disease 2019 (COVID-19) is expanding rapidly, which made it as one of top priorities for scientists to develop novel treatment strategies. Researchers are racing to develop treatments based on antibodies to block and/or neutralize the coronavirus in affected patients. Initially, the genetic and structural similarity of the virus to severe acute respiratory syndrome coronavirus (SARS-CoV) created the potential for understanding disease pathogenesis. Researchers have published reports of specific monoclonal antibodies against to COVID-19 (B38, H4, 47D11) and hope that this method is effective. As well as studies on patients who are plasma therapy, the patient's condition shows improvement. The evidence for these studies is very promising and demonstrates the potential of monoclonal antibody therapy as a therapeutic approach and prevention of covid-19 infection.El texto completo de este artículo está disponible en PDF.
Keywords : COVID-19, SARS-CoV, Treatment, Monoclonal antibodies